• New member in our staff: Dr Raimond Heukers.

Dr Raimond Heukers studied Laboratory Research in Enschede and Biology of Disease  at Utrecht University. He obtained his PhD at Utrecht University with his thesis entitled ‘Clustering-Induced, Clathrin-Mediated Endocytosis for cancer therapy’. His PhD research focussed on the use of VHHs in fundamental research, therapy and molecular imaging. After his PhD, Raimond underwent additional training in antibody-discovery at arGEN-X in Belgium. Therefore, he is well trained in the field of antibody/VHH discovery and research. As a postdoctoral fellow at the VU University in Amsterdam, he joined the Molecular Pharmacology group of Prof Martine Smit, a renowned expert in the field of GPCRs. There, Raimond successfully established a VU-VHH platform for the selection and characterization of VHHs that binds and/or modulate different types of GPCRs. Besides being engaged with QVQ, Raimond will remain closely involved with the ongoing GPCR-VHH research lines at the VU.

We are confident that with Raimond on board we can even better fulfil the present and future targets our clients will give us.

 

VHH-related publications of Raimond Heukers:

  • de Wit RH, Heukers R, Brink H, Arsova A, Maussang D, Cutolo P, Bachelerie F, Smit MJ., 2017, CXCR4-specific nanobodies as potential therapeutics for WHIM syndrome. J Pharmacol Exp Ther. 363:35-44
  • van Driel PB, Boonstra MC, Slooter MD, Heukers R, Stammes MA, Snoeks TJ, de Bruijn HS, van Diest PJ, Vahrmeijer AL, van Bergen En Henegouwen PM, van de Velde CJ, Löwik CW, Robinson DJ, Oliveira S., 2016, EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer. J Control Release. 229:93-105
  • Hultberg A., Morello V., Huyghe L., De Jonge N., Blanchetot C., Hanssens V., De Boeck G., Silence K., Festjens E., Heukers , Roux B., Lamballe F., Ginestier C., Charafe-Jauffret E., Maina F., Brouckaert P., Saunders M., Thibault A., Dreier T., de Haard H., Michieli P., 2015, Depleting MET-Expressing tumor cells by ADCC provides a therapeutic advantage over inhibiting HGF/MET signaling., Cancer Res. 75(16):3373-83.
  • Heukers R., van Bergen en Henegouwen P.M.P., Oliveira S., Nanobody-photosensitizer conjugates for targeted photodynamic therapy. 2014 Nanomedicine, (7):1441-51.
  • Heukers R., Altintas I., Raghoenath S., de Zan E., Pepermans R., Roovers R.C., Haselberg R., Henning W.E., Schiffelers R.M. Kok R.J., van Bergen en Henegouwen P.M.P., 2014, Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles. Biomaterials. 35(1):601-10.
  • Heukers R., Vermeulen J.F., Fereidouni F., Bader A.N., Voortman J., Roovers R.C., Gerritsen H.C., van Bergen en Henegouwen P.M.P., 2013, EGFR endocytosis requires its kinase activity and N-terminal transmembrane dimerization motif. J Cell Sci. 126(Pt 21):4900-12.
  • Oliviera S., Heukers R., Somkom J., Kok R.J., van Bergen en Henegouwen P.M.P., 2013, Targeting tumors with nanobodies for cancer therapy. J Control Release. 172(3):607-617.
  • van der Meel R., Oliveira S., Altintas I., Heukers R., Pieters E.H., van Bergen en Henegouwen P.M.P., Storm G., Hennink W.E., Kok R.J., Schiffelers R.M., 2013, Inhibition of tumor growth by targeted anti-EGFR/IGF-1R Nanobullets depends on efficient blocking of cell survival pathways., Mol Pharm. 10(10):3717-27.

Altintas I., Heukers R., van der Meel R., Lacombe M., Amidi M., van Bergen en Henegouwen P.M.P., Hennink W.E., Schiffelers R.M., Kok R.J., 2013, Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells., J Control Release. 165(2):110-8.